MedTrace Logo

DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

NCT01614366 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2015-11-13

No results posted yet for this study

Summary

The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.

Conditions

Interventions

DRUG

AM 5 + DM 0

Amlodipine 5 mg + DMTA07 0mg, once daily

DRUG

AM 5 + DM 2.5

Amlodipine 5 mg + DMTA07 2.5mg, once daily

DRUG

AM 5 + DM 7.5

Amlodipine 5 mg + DMTA07 7.5mg, once daily

DRUG

AM 5 + DM 30

Amlodipine 5 mg + DMTA07 30mg, once daily

Sponsors & Collaborators

  • TSH Biopharm Corporation Limited

    lead INDUSTRY

Principal Investigators

  • Jaw-Wen Chen, Doctor · VGHTP

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01614366 on ClinicalTrials.gov